Sashi Kesavapany, PhD, is Chief Executive Officer and Co-Founder of LiberaTx, and has 20 years’ post-PhD experience in target and disease biology. After two postdoctoral stints in KCL and at the NIH, he moved his neurodegenerative R&D into translational models of Alzheimer’s disease and neuroinflammation. He was an Assistant Professor in NUS until 2009. He then headed in vitro, in vivo and pharmacological teams in GlaxoSmithKline R&D, working on a number of programmes in the R&D portfolio, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and spinal muscular atrophy. He has routinely managed hitID and in vivo PK/PD experiments that progress molecules through the drug discovery pipeline.